Microcap Ledger Nexentis Technologies Inc. $NXTS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 1,453,333 [10-Q 2026-08-13]
What the company doesAI summary of filing
Nexentis Technologies Inc. is a holding company with operations in drug discovery and renewable energy. The company's primary focus is MitoCareX Bio Ltd., a wholly-owned subsidiary that develops small molecule cancer therapeutics targeting mitochondrial carrier proteins (SLC25A family) for non-small cell lung cancer and pancreatic cancer treatment. MitoCareX is a pre-revenue, clinical-stage company that uses computational chemistry and structural biology platforms to identify and optimize drug candidates; it has identified a lead compound (hit compound 1) validated in preclinical models. The company generates revenue through service agreements related to its former Save Foods subsidiary (which Nexentis divested in March 2026) and holds a 70 percent stake in a renewable energy project in Europe, with plans to monetize its proprietary MITOLINE™ algorithm through licensing partnerships with pharmaceutical companies. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$17.73M | −$1.96M | $7.62M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$4.00M | −$3.81M | $3.83M | [10-K 2026-03-31] |
| FY ended Dec 2024 | $210.0K | −$5.19M | −$3.42M | $1.92M | [10-K 2025-03-31] |
- Quarterly cash burn
- −$979.0K
- Cash runway Estimate
- ~23.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 11,408,237 | [10-Q 2024-11-14] |
| 2025-03-31 | 17,812,404 | [10-K 2025-03-31] |
| 2025-05-15 | 26,408,912 | [10-Q 2025-05-15] |
| 2025-08-14 | 33,356,412 | [10-Q 2025-08-14] |
| 2025-11-13 | 2,712,883 | [10-Q 2025-11-13] |
| 2026-03-31 | 5,111,362 | [10-K 2026-03-31] |
| 2026-05-14 | 730,459 | [10-Q 2026-05-14] |
| 2026-08-13 | 1,453,333 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-07-13; declared effective 2026-07-17 [S-1 2026-07-13]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-03] |
| 2025-10-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-08] |
| 2025-03-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-31] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-02-09 | Zakai Shlomo | grant | 50,000 | — | [4 2026-02-11] |
| 2026-02-09 | Barda Lital | grant | 50,000 | — | [4 2026-02-11] |
| 2026-02-09 | Weiss Amitay | grant | 116,286 | — | [4 2026-02-11] |
| 2026-02-09 | Palach David | grant | 100,000 | — | [4 2026-02-11] |
| 2026-01-29 | Lee Eun Young | sell | 127 | $1.35 | [4 2026-03-26] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | 8-K | Material agreement entered |
| 2026-10-05 | PRE 14A | Proxy statement |
| 2026-09-03 | 8-K | Listing notice or transfer |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Auditor change |
| 2026-07-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-13 | S-1 | Registration statement |
| 2026-06-23 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-22 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-06-15 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-12 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-05-27 | 8-K | Material agreement entered; New financial obligation |
Alerts for $NXTS
Email me when Nexentis Technologies Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.